Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2013

View Archived Issues

SOMCL-12-81 as a potent ALK inhibitor with promising oncolytic activity

Dinaciclib plus MK-2206 evaluated in pancreatic cancer trial

Genethon discusses gene therapy for Wiskott-Aldrich syndrome, phase I/II results published

Roche and immatics biotechnologies sign cancer vaccine collaboration

PKM2 identified in ovarian serous adenocarcinoma samples

3-V Biosciences describes TVB-3166, a novel oncolytic FAS inhibitor

Epizyme's EPZ-5676 shows promise in an ongoing phase I trial

Acadia Pharmaceuticals begins pimavanserin trial for Alzheimer's disease psychosis

Enrollment complete in the DIRECT II study of Svelte Medical Systems' drug-eluting stent

Early clinical results presented for the novel antimalarial agent OZ-439

First patient treated in study of DNX-2401 and temozolomide for recurrent glioblastoma

Japanese researchers present novel Toll-like receptor antagonists

Defibrotide receives orphan drug status in Australia

New LRRK2 modulators patented by Genentech and Roche for Parkinson's disease

Takeda prepares new prostanoid EP2 receptor agonists

Spanish scientists divulge novel tamoxifen derivatives for cancer and other disorders

New DDR1 inhibitors for cancer disclosed by Chugai Pharmaceutical

Adocia begins trial of combination of long- and fast-acting insulin analogues

Sorrento to acquire antibody-drug conjugation technology from Concortis Biosystems

MicroBiome Therapeutics advances development of NM-504

Ono Pharmaceutical reports data from phase II/III study of ONO-2745

FDA advisory committee recommends approval of circadian regulator tasimelteon

Otsuka Pharmaceutical recaps highlights of second quarter of fiscal 2013

Novogen reports discovery in program for degenerative disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...